← All trials
NCT03745261
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2018
- Primary completion
- Dec 31, 2019
- Completion date
- Jun 30, 2020
- First posted
- Nov 19, 2018
- Last posted
- Nov 19, 2018
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Henan University of Traditional Chinese MedicineLead sponsor
- Guangzhou Pharmaceucal Company LimitedCollaborator
- Henan University of Traditional Chinese MedicineOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.